会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Phosphonyldipeptides useful in the treatment of cardiovascular diseases
    • 可用于治疗心血管疾病的膦酰二肽
    • US5760285A
    • 1998-06-02
    • US702701
    • 1996-09-13
    • Gabriele NorciniGabriele MorazzoniFrancesco Santangelo
    • Gabriele NorciniGabriele MorazzoniFrancesco Santangelo
    • A61K38/00C07K5/06C07F9/22A01N57/36
    • C07K5/06191A61K38/00
    • Compounds of formula (II) ##STR1## wherein R is a biphenyl group optionally substituted by one or more substituents, the same or different, selected among halogen atoms, hydroxy groups, alkoxy, alkyl or thioalkyl groups having from 1 to 6 carbon atoms in the alkyl moiety, carboxylic groups, nitro groups, amino, mono- or di-alkylamino groups having from 1 to 6 carbon atoms in the alkyl moiety; R.sub.1 is a hydrogen atom or a straight or branched C.sub.1 -C.sub.4 allyl; R.sub.2 is a straight or branched C.sub.1 -C.sub.6 alkyl or an arylalkyl having from 1 to 6 carbon atoms in the alkyl moiety wherein the aryl is a phenyl, a naphthyl or a 5 or 6 membered aromatic heterocycle with one or two heteroatoms selected among nitrogen, oxygen and sulphur, optionally substituted as above indicated for the R substituent; R.sub.3 is a straight or branched C.sub.1 -C.sub.6 alkyl, optionally containing one or more fluorine atoms, or an arylalkyl having from 1 to 6 carbon atoms in the alkyl moiety; the carbon atoms marked with an asterisk are asymmetric carbon atoms; and their pharmaceutically acceptable salts, are described. The compounds of formula (II) are useful in the treatment of cardiovascular diseases.
    • PCT No.PCT / EP95 / 01322 Sec。 371日期1996年9月13日 102(e)1996年9月13日PCT PCT 1995年4月11日PCT公布。 WO95 / 28417 PCT出版物 日期:1995年10月26日化学式(II)其中R是任选被一个或多个选自卤素原子,羟基,烷氧基,烷基或硫代烷基中的一个或多个相同或不同的取代基取代的联苯基 在烷基部分具有1至6个碳原子,在烷基部分具有1至6个碳原子的羧基,硝基,氨基,一或二烷基氨基; R1是氢原子或直链或支链C1-C4烯丙基; R2是直链或支链的C 1 -C 6烷基或在烷基部分具有1至6个碳原子的芳基烷基,其中芳基是苯基,萘基或具有一个或两个选自氮, 氧和硫,任选地被如上述R取代基所取代; R3是任选地含有一个或多个氟原子的直链或支链C 1 -C 6烷基或在烷基部分具有1至6个碳原子的芳基烷基; 标有星号的碳原子是不对称碳原子; 及其药学上可接受的盐。 式(II)的化合物可用于治疗心血管疾病。
    • 6. 发明授权
    • Benzazine derivatives as phosphodiesterase 4 inhibitors
    • 苯并嗪衍生物作为磷酸二酯酶4抑制剂
    • US06358973B1
    • 2002-03-19
    • US09806496
    • 2001-04-13
    • Mauro NapoletanoGabriele NorciniGiancarlo GranciniFranco PellaciniGabriele MorazzoniLorenzo Pradella
    • Mauro NapoletanoGabriele NorciniGiancarlo GranciniFranco PellaciniGabriele MorazzoniLorenzo Pradella
    • C07D4006
    • C07D401/06
    • Compounds of formula I: wherein A is a heterocycle containing a nitrogen atom and optionally saturated or unsaturated and optionally further substituted by an oxo group (═O); R is: hydrogen, cyano, (C1-4)alkoxycarbonyl, carbamoyl; optionally substituted (C4-7)-cycloalkyl, aryl or heterocycle; (C1-8)alkyl, (C2-8)alkenyl or (C2-8)alkynyl optionally branched and/or substituted by (C4-7) cycloalkyl, aryl or heterocycle; aryloxy, heterocyclyloxy, aryl(C1-4)alkoxy, heterocyclyl(C1-4)alkoxy, amino substituted by one or two (C1-4)alkyl group(s), aryl-amino, heterocyclyl-amino, aryl(C1-4)alkyl-amino, or heterocyclyl(C1-4)alkylamino; Y is methylene or ethylene; W is an optionally substituted aryl or heterocycle; R1 is hydrogen, (C4-7)cycloalkyl or a (C2-8)alkyl, (C2-8)alkenyl or (C2-8)alkynyl group optionally substituted by hydroxy, oxo, (C4-7)cycloalkyl, aryl or heterocycle, and optionally interrupted by one or more heteroatom(s) or heterogroup(s); R2 is a (C1-6)alkyl or polyfluoro(C1-6)alkyl group; the N→O derivatives of the compounds of formula I and the pharmaceutically acceptable salts thereof. The compounds of formula (I) are PDE 4 inhibitors and may be used in compositions and methods involving PDE 4 inhibition.
    • 式I化合物:其中A是含有氮原子,任选饱和或不饱和并任选进一步被氧代基(= O)取代的杂环; R为:氢,氰基,(C 1-4)烷氧基羰基,氨基甲酰基; 任选取代的(C 4-7) - 环烷基,芳基或杂环; (C 1-8)烷基,(C 2-8)烯基或任选被(C 4-7)环烷基,芳基或杂环支链和/或取代的(C 2-8)炔基; 芳氧基,杂环氧基,芳基(C 1-4)烷氧基,杂环基(C 1-4)烷氧基,被一个或两个(C 1-4)烷基取代的氨基,芳基 - 氨基,杂环基 - 氨基,芳基 )烷基 - 氨基或杂环基(C 1-4)烷基氨基; Y是亚甲基或亚乙基; W是任选取代的芳基或杂环; R1是氢,(C4-7)环烷基或(C2-8)烷基,(C2-8)烯基或(C2-8)炔基,任选被羟基,氧代,(C 4-7)环烷基,芳基或杂环 并且任选被一个或多个杂原子或杂团中断; R2是(C1-6)烷基或多氟(C1-6)烷基; 式I化合物的N-> O衍生物及其药学上可接受的盐。 式(I)化合物是PDE 4抑制剂,可用于涉及PDE4抑制的组合物和方法。